Home・Lista de Ações・Arvinas Inc

Arvinas Inc

Fechado

SetorSaúde

8.94 11.75

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

9.61

Indicadores-chave
By Trading Economics
Rendimento	9.8M -58M
Vendas	6.1M 16M
EPS	-0.9
Margem de lucro	-369.231
Funcionários	246
EBITDA	9.6M -56M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+80.77% upside

Dividendos
By Acuity
Próximos Ganhos	4 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-103M 520M
Abertura anterior	-2.81
Fecho anterior	8.94

Sentimento de Notícias

By Acuity

43%

57%

160 / 340 Ranking em Healthcare

Arvinas Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2026, 20:02 UTC

Social Media

News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3 de ago. de 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31 de jul. de 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29 de jul. de 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28 de jul. de 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24 de jul. de 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22 de jul. de 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21 de jul. de 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Comparação entre Pares

Variação de preço

Arvinas Inc Previsão

Preço-alvo

By TipRanks

80.77% parte superior

Previsão para 12 meses

Média 14.57 USD 80.77%

Máximo 20 USD

Mínimo 6 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Arvinas Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Arvinas Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

160 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.